A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
about
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewRandomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularA comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.Emerging treatment for advanced lung cancer with EGFR mutation.Gender difference in the prognostic role of interleukin 6 in oral squamous cell carcinoma.Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutationsCombination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.Erlotinib in the treatment of advanced non-small cell lung cancer: an update for cliniciansPredictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase InhibitorsMulticenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.Saudi lung cancer management guidelines 2017.Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis.The continued EGFR-TKI with cytotoxic chemotherapy at progression-poison or medicine?
P2860
Q26471909-29210424-B1C8-4834-AC9C-2093C569F32CQ26828860-A2260B6A-5C33-439B-AEDD-D22D21DE73CBQ27022535-0F5D93D4-B0D0-495A-87F1-5BD941AC7774Q33873095-D2EDDBBE-D949-4AB6-A02D-E7D901D7FDC5Q34159011-1C566D03-4EB2-4AF0-B91A-5F56DAFA4826Q34387448-547CDE63-2622-49A2-8F40-46664E5BD1A7Q34483953-8B242547-7105-44DF-8B59-C78A11549BB5Q34491048-5BF8FEE7-0536-477A-B0A8-B733EA3A8B28Q34503883-A235382C-F592-4A37-897C-A706D89F5CBCQ35043675-B32C9964-0723-4E4F-B794-9D3AC8E7066AQ35107524-C35DFAED-6B68-4732-994A-00EC9BF1ED0FQ35628121-F5CB0082-A551-40CC-80CF-46ECF6112F59Q35824117-1EA6FA8B-BCA9-4E59-9F70-4E36CE68A521Q36028888-7284A7B1-35BE-4938-9268-3ADCA303A687Q36178775-63A99F9D-9A7A-4D66-A21A-DD05C0E2A43AQ36999705-F7A39974-0EF9-4005-ADCC-1487D317C118Q37301477-8DB9016B-0928-4D9A-A1D2-E98E0CD396A8Q37357699-89055C71-6B40-4529-9A25-5F040EF889C7Q37698439-B12E3153-1E40-40EF-87E2-88440CF79378Q38862340-929821A6-72A3-4F96-9EC1-866A00CB24C8Q38891976-AA4ACE59-81D1-454B-8DFE-6EE5F1A49445Q38983980-65BC8FFE-B92A-4224-B60B-C58BEF424B18Q39455567-01AFD8EF-FE4A-4555-8339-76FAC958FBE9Q41678123-0B58ED30-2C6B-4CBF-A67B-6FFD87B1DC33Q43780769-3B0A2697-220A-4663-8834-22F5F29FC72EQ47096145-39532360-256E-42B6-AA0F-5D541E71672DQ48352757-4220A2DB-5BF1-4453-921A-A72A203BF86BQ50073382-164ED9EE-C1F5-46E0-B46C-F27EE09850F2Q53647606-33B89767-97D7-4A0F-8B93-B87CB23758CAQ54114243-4280CB67-6F06-4BC1-87FC-5A0DDC9CCC4BQ55044764-2B5C1088-363C-41CA-98E6-067195A25A5FQ55223055-FEF017D3-CDB5-439C-997E-35F8B54AA952
P2860
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized, phase II, biomar ...... ced non-small-cell lung cancer
@ast
A randomized, phase II, biomar ...... ced non-small-cell lung cancer
@en
type
label
A randomized, phase II, biomar ...... ced non-small-cell lung cancer
@ast
A randomized, phase II, biomar ...... ced non-small-cell lung cancer
@en
prefLabel
A randomized, phase II, biomar ...... ced non-small-cell lung cancer
@ast
A randomized, phase II, biomar ...... ced non-small-cell lung cancer
@en
P2093
P2860
P356
P1476
A randomized, phase II, biomar ...... ced non-small-cell lung cancer
@en
P2093
Bret Wacker
D Ross Camidge
David W Sternberg
Fairooz Kabbinavar
Frank Richardson
Fred R Hirsch
Fredrick M Schnell
Jason Rusk
Katherine Richardson
Marileila Varella-Garcia
P2860
P304
P356
10.1200/JCO.2010.34.4929
P407
P577
2011-08-08T00:00:00Z